TriangleHEALTH PROFESSIONAL · SOURCE READING
Highest-Risk Patients With Blastoid Morphology and/or a TP53 Pathogenic Variant
Source: Mantle Cell Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Aggressive Mantle Cell Lymphoma
Although the prior standard of care for untreated MCL was chemoimmunotherapy including high-dose cytarabine and autologous SCT, patients with TP53-altered MCL have had poor outcomes with this regimen, with a median PFS of under 1 year.[22,23] BTK inhibitors combined with other immunological or targeted molecules are particularly applicable for testing. Consolidation with allogeneic SCT or trials studying chimeric antigen receptor T cells or bispecific antibodies are also warranted after treatment response.[24]
Evidence (new combinations for highest-risk patients):
A phase II trial included 25 patients with TP53 pathogenic variants who required therapy because of significant constitutional symptoms, cytopenias, symptomatic splenomegaly, progressive nodal involvement, or significant organ compression or involvement. Patients received zanubrutinib (the selective BTK inhibitor), obinutuzumab (the humanized anti-CD20 monoclonal antibody), and venetoclax (the BCL inhibitor, with a 5-week ramp-up beginning on day 1 of the third cycle).[25]
Source links and citations
A phase II trial included 25 patients with TP53 pathogenic variants who required therapy because of significant constitutional symptoms, cytopenias, symptomatic splenomegaly, progressive nodal involvement, or significant organ compression or involvement. Patients received zanubrutinib (the selective BTK inhibitor), obinutuzumab (the humanized anti-CD20 monoclonal antibody), and venetoclax (the BCL inhibitor, with a 5-week ramp-up beginning on day 1 of the third cycle).[25]
With a median follow-up of 28.2 months, the overall response rate was 96% and the complete response rate was 68% at the start of cycle three. The 2-year PFS rate was 72% (95% CI, 56%–92%), and the 2-year OS rate was 76% (95% CI, 79%–100%).[25][Level of evidence C3]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice